BioLinker secures $1.7M to build AI-powered biotech lab in Manaus
Brazilian synthetic biology startup BioLinker raised $1.7 million to construct an automated laboratory at the Amazon BioBusiness Center in Manaus and expand its workforce. Axcell, an accelerator focused on Amazonian businesses, contributed $1.4 million, while the São Paulo Research Foundation (FAPESP) provided approximately $240,000 through its PIPE Phase 2 program.
Founded in 2018 by scientists from the University of São Paulo, BioLinker develops and manufactures recombinant proteins using synthetic biology and genetic engineering. The company serves research institutions, diagnostics firms, and industrial clients across health, agriculture, and biotechnology sectors. BioLinker already generates recurring revenue and expects the new capital to fund three years of operations.
The funding round remains open. According to reporting by Startups Brazil, BioLinker is pursuing an international investor to accelerate its AI development cycle and support a Series A round planned within two years.
Axcell, founded in 2022, has backed more than 30 companies and prioritizes sustainability and social impact in the Amazon region. Axcell's investment comes from a fund capitalized by companies operating in the Manaus Free Trade Zone, which are required to allocate resources to innovation.
Planning a hire?
Talk through the best hiring option
This article usually leads to one practical question: should you use country guide or it recruitment? We can help you choose quickly.
Simple next step
Start with country guide and we will help you pick the best hiring setup.
How BioLinker's Amazon expansion signals biotech talent demand in Brazil
BioLinker's Manaus facility will deploy robotics to perform high-throughput screening, a method that generates biological data at scale for training artificial intelligence models. The lab will be the only facility in Brazil equipped with this technology for commercial use, according to company statements. The infrastructure will also support expanded DNA synthesis capacity, reducing Brazil's dependence on imported genetic material.
The company plans to double its team to support the new lab and scale operations. BioLinker plans to double its team from 12 to 24 employees as it builds an automated laboratory at the Amazon BioBusiness Center in Manaus. Employers hiring talent in Brazil's biotech sector will face competition for candidates with expertise in recombinant protein production, laboratory automation, and bioinformatics.
BioLinker's expansion underscores demand for AI engineers for biotech applications. The company's strategy centers on using machine learning to accelerate protein discovery and optimization, requiring specialists who can bridge computational modeling and wet-lab experimentation. As BioLinker scales its data generation capacity, roles in machine learning operations, biological data annotation, and algorithm development will become critical.
The Manaus location offers strategic advantages beyond regulatory incentives. The Amazon BioBusiness Center provides infrastructure for companies working with regional biodiversity, positioning BioLinker to access unique biological resources while contributing to local economic development. For multinational employers evaluating Brazilian biotech hubs, the Manaus ecosystem now represents a viable alternative to traditional clusters in São Paulo and Rio de Janeiro.
Emerging opportunities in Brazil's automated biology and AI workforce
BioLinker's funding and expansion plans illustrate how synthetic biology startups are creating demand for hybrid skill sets combining life sciences training with engineering and data expertise. The company's focus on automation and AI-driven protein design requires employees who can operate robotic systems, manage large biological datasets, and interpret computational predictions in experimental contexts.
Brazil's biotech sector has historically concentrated on agricultural applications and industrial enzymes. BioLinker's emphasis on recombinant proteins for diagnostics and research represents a shift toward higher-value products requiring more specialized talent. The company's ability to attract and retain skilled workers in Manaus will test whether incentives and infrastructure can offset the pull of established biotech centers.
FAPESP's PIPE Phase 2 funding supports biotech ventures in scaling their operations. PIPE, or Research for Innovation in Small Businesses, provides non-dilutive capital to companies transitioning from R&D to commercial production. BioLinker received FAPESP PIPE Phase 2 funding, which contributed about $240K to the company's $1.7M funding round.
For employers planning biotech operations or partnerships in Latin America, BioLinker's trajectory offers a case study in how regional incentives, academic partnerships, and targeted infrastructure investments can support specialized manufacturing. The company's plan to produce DNA domestically addresses a supply chain vulnerability affecting research institutions and biotech firms across Brazil. As the facility becomes operational, it may catalyze further investment in complementary services such as oligonucleotide synthesis, plasmid production, and contract research.
BioLinker's workforce expansion represents a significant increase, but longer-term growth will depend on securing Series A funding and scaling production. The open funding round and active search for an international investor suggest the company is positioning itself for accelerated growth, which would likely drive additional hiring in technical, commercial, and operational roles.